Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
18 reports, 8 independent
Updated Sep 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 18
- Developments
- 12
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.Sub-event
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.Sub-event
Moderna's stock lagged behind Regeneron's surge despite the vaccine development.1 source
- Moderna combined its vaccine with Merck's Keytruda drug.Sub-event
- Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.Sub-event
- Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.Sub-event
- Moderna and Merck developed a new therapy.Sub-event
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.Sub-event
Show 4 earlier steps
- Moderna's study combines with Merck's Keytruda, and Jim Cramer advises investors on Moderna's stock.Sub-event
Moderna and Merck are collaborating on the development of an intismeran cancer vaccine.1 source
- Moderna and Merck are collaborating on Intismeran autogene, with production planned for Laval and Canadian authorization granted.Sub-event
Moderna develops personalized cancer vaccine platform with Merck KGaA.1 source
Keep exploring
The entities involved
-
Merck KGaA
German multinational science and technology company
-
Moderna
American biotechnology company
-
Merck
public company in Indonesia
Related events
- Moderna and Merck co-developed an experimental cancer vaccine, while also forming a partnership regarding tensor processing units with Google and Marvell Technology.
- Moderna, Memorial Sloan Kettering Cancer Center, and American Cancer Society are developing personalized cancer vaccine technology.
- Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
- Moderna and Merrill jointly developed skin cancer vaccine trials.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
Coverage
Newest first; wire copies grouped- yahoo.com
- yahoo.com
- yahoo.com
- spokesman.com
- fox10phoenix.com
- investors.com
- arabnews.com
- shafaqna.com
- Insider MonkeyModerna, Inc. (MRNA) Expands Into Oncology with Pan-Tumor Vaccine We recently published 11 Best Cancer Stocks to Buy Right Now. Moderna, Inc. stands fifth among them. Moderna, Inc. (NASDAQ:MRNA) stan
- ZacksCan Keytruda Sustain Merck's Growth Through the Rest of 2025? Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor a
- ZacksMerck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? Earlier this week, Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The de
- Unknown outlet
- Unknown outlet